Day: March 2, 2020

Dr. Rajamannan Replies to FDA’s Demands of New Evidence Surrounding Harm to Patients in an Open Letter to Members of Congress, the FDA Commissioner Hahn and HHS Secretary Azar

FDA Accepts MorphoSys’ Biologics License Application (BLA) and Grants Priority Review for Tafasitamab and Lenalidomide for the Treatment of Relapsed/Refractory DLBCL

FDA Accepts MorphoSys' Biologics License Application (BLA) and Grants Priority Review for Tafasitamab and Lenalidomide for the Treatment of Relapsed/Refractory...

error: Content is protected !!